The clinical and etiological diversity found among people with a diagnosis of autism spectrum disorder (ASD) is a critical factor and an obstacle in the development of new treatments. So far, no biomarker has been identified. Autism has long been recognized, based on outcome studies, as a heterogeneous category. In 1943, Leo Kanner, MD, introduced and systematically described defining characteristic features that were largely adopted in the DSM-III diagnosis of early infantile autism.1 Kanner’s clinical follow-up study of his first 11 cases in 1971 revealed considerable heterogeneity in outcomes.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Harris JC. The Necessity to Identify Subtypes of Autism Spectrum Disorder. JAMA Psychiatry. Published online August 21, 2019. doi:10.1001/jamapsychiatry.2019.1928
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: